EUACCBack to showcase
ONEGO BIO

ONEGO BIO

Grant-FundedCORDIS

Novel precision fermentation process to produce animal-free bioidentical ovalbumin

Visit website
🇫🇮 Helsinki, Finland·Founded 2022·11-50 employees·onego.bio
Climate · Biotech · AgriTech
Eggs are critically important in the global food system due to functional and nutritional properties; yet the egg market and supply chains are in crisis due to cage-free requirements and avian flu. Onego Bio will make it possible to manufacture egg protein entirely animal-free. We developed a highly-scalable precision fermentation process using the patented Trichoderma reesei cellular-based production to produce animal-free ovalbumin. We produce bioidentical egg protein with cost parity and 87% lower CO2 emissions compared to traditional animal-derived eggs. Ovalbumin is the most important egg protein, responsible for the essential ingredient performance. This single protein ovalbumin can solve all current challenges in the egg market and supply chain. Our product, Bioalbumen provides the nutritional and functional upsides of egg protein, without the environmental, ethical and safety-related drawbacks. Our manufacturing method stabilises the food supply chain and increases food security.
EU Grants€2.5M
Open to funding

Team

MI

Maija Itkonen

Founder

All-time revenue
MRRPrivate••••••
FounderMaija Itkonen
Founded2022
🇫🇮Finland
RevenuePrivate
Revenue data is privateThis company has chosen not to share revenue metrics

Startup insights

Business detailsB2B
ClimateBiotechAgriTech
Tags:ClimateBiotechAgriTech
Looking for:InvestmentPartnerships